GSK Pharma Q1 profit up 16% at ₹237.18 cr

GlaxoSmithKline Pharmaceuticals Ltd on Monday reported a 16 per cent rise in consolidated net profit to ₹237.18 crore in the first quarter ended June 30, 2026.

The company had posted a consolidated net profit of ₹205 crore in the corresponding period of the preceding financial year, GlaxoSmithKline Pharmaceuticals Ltd (GSK India) said in a regulatory filing.

Consolidated revenue from operations in the first quarter of FY27 stood at ₹938.44 crore against ₹805.17 crore in the year-ago period, it added.

Total expenses in Q1 FY27 increased to ₹659.75 crore, compared to ₹569.91 crore in the same period a year ago, the company said.

The first quarter performance reflects continued progress in the company's portfolio transformation strategy, supplemented by execution excellence and a favourable base effect from the comparable period last year, GSK India said.

Commenting on the performance, GSK India MD Bhushan Akshikar said,"GSK India's broad-based growth demonstrates the resilience of the core general medicines and vaccines portfolio and the growing contribution of the innovative business." This growth was enabled by a relentless focus on scientific excellence, sharper execution in the field and meaningful investments in technology and talent development, he added.

“With a strong innovation pipeline and launch opportunities ahead, we are well-positioned to deliver sustainable growth and meaningful impact for millions of patients in India,” Akshikar said.

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.